

17 April 2024

Privatisation by way of scheme of arrangement

Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Purchase / Sale	Number of shares	Price per share	Resultant balance (including those of any person with whom there is an agreement or understanding)	Percentage of class (including those of any person with whom there is an agreement or understanding)
Lin Huibin	5 April 2024	Purchase	10,000	\$0.0000	19,967	0.0032%

End

Note:

Lin Huibin is a Class (3) associate connected with the Offeree company.

Dealings were made for her own account.

On 5 April 2024, 10,000 share awards were vested on Lin Huibin pursuant to the Post-IPO RSU Plan adopted by the Company.

This form was received by the Executive on 17 April 2024.